comparemela.com

Latest Breaking News On - Allogene therapeutics daily - Page 1 : comparemela.com

Insider Selling: Allogene Therapeutics, Inc. (NASDAQ:ALLO) Director Sells 11,200 Shares of Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) Director Franz B. Humer sold 11,200 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $2.34, for a total value of $26,208.00. Following the completion of the sale, the director now owns 255,253 […]

Canada
Franzb-humer
Piper-sandler
Canada-life-assurance
Pricet-rowe-associates-inc
Allogene-therapeutics-company-profile
Nasdaq
Allogene-therapeutics-inc
Susquehanna-fundamental-investments
Jpmorgan-chase-co
Securities-exchange-commission
Headlands-technologies

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month […]

Canada
Switzerland
Alps
Switzerland-general
Swiss
Arie-belldegrun
Piper-sandler
Jpmorgan-chase-co
Securities-exchange-commission
Royal-bank
Sg-americas-securities
Allogene-therapeutics-inc

Allogene Therapeutics (NASDAQ:ALLO) Now Covered by Analysts at Piper Sandler

Piper Sandler initiated coverage on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a report published on Friday, Marketbeat reports. The brokerage issued an overweight rating and a $11.00 target price on the stock. ALLO has been the subject of several other research reports. Royal Bank of Canada reissued an outperform rating and issued […]

Arizona
United-states
Canada
Stifel-nicolaus
Piper-sandler
Arie-belldegrun
Victory-capital-management-inc
Harbor-capital-advisors-inc
Vontobel-holding-ltd
Allogene-therapeutics-inc
Royal-bank
Jpmorgan-chase-co

Truist Financial Reiterates Buy Rating for Allogene Therapeutics (NASDAQ:ALLO)

Truist Financial reiterated their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $17.00 price target on the stock. A number of other analysts also recently weighed in on ALLO. Royal Bank of Canada reiterated an outperform rating […]

Alps
Switzerland-general
Switzerland
Canada
Swiss
Stifel-nicolaus
Citigroup-inc
Allogene-therapeutics-inc
Jpmorgan-chase-co
Alps-advisors-inc
Sg-americas-securities
Royal-bank

Q2 2024 EPS Estimates for Allogene Therapeutics, Inc. Lowered by William Blair (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Research analysts at William Blair decreased their Q2 2024 EPS estimates for shares of Allogene Therapeutics in a research report issued on Tuesday, May 14th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.39) for the quarter, down from […]

Canada
Arizona
United-states
Stifel-nicolaus
William-blair
Allogene-therapeutics-company-profile
Victory-capital-management-inc
Principal-financial-group-inc
Harbor-capital-advisors-inc
Vontobel-holding-ltd
Royal-bank
Allogene-therapeutics-inc

vimarsana © 2020. All Rights Reserved.